

Interconnection between circadian clocks and thyroid function

Keisuke Ikegami¹, Samuel Refetoff^{2,3}, Eve Van Cauter² & Takashi Yoshimura^{4,5*}

¹ Department of Physiology, School of Medicine, Aichi Medical University, 1-1 Yazakokarimata, Nagakute 480-1195, Japan

² Department of Medicine, The University of Chicago School of Medicine, 5841 S. Maryland Ave., Chicago, IL 60637, USA

³ Department of Pediatrics and Committee on Genetics, The University of Chicago, 5841 S. Maryland Ave., Chicago, IL 60637, USA

⁴ Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan

⁵ Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan

*Email: takashiy@agr.nagoya-u.ac.jp

Abstract

Circadian rhythmicity is an approximately 24h cell-autonomous period driven by transcription–translation feedback loops of specific genes, which are referred to as ‘circadian clock genes’. In mammals, the central circadian pacemaker, which is located in the hypothalamic suprachiasmatic nucleus, controls peripheral circadian clocks. The circadian system regulates virtually all physiological processes, which are further modulated by changes in external environment, such as light exposure and timing of food intake. Chronic circadian disruption caused by shift work, travel across time zones or irregular sleep-wake cycles has long-term consequences on our health and is an important lifestyle factor that contributes to the risk of obesity, type 2 diabetes mellitus and cancer. Although the hypothalamic–pituitary–thyroid axis is under the control of the circadian clock via the suprachiasmatic nucleus pacemaker, daily TSH secretion profiles are disrupted in some patients with hypothyroidism and hyperthyroidism. Disruption of circadian rhythms has been recognized as a perturbation of the endocrine system and of cell cycle progression. Expression profiles of circadian clock genes are abnormal in well-differentiated thyroid cancer but not in the benign nodules or a healthy thyroid. Therefore, the characterization of the thyroid clock machinery might improve the preoperative diagnosis of thyroid cancer.

Key points

- The hypothalamic–pituitary–thyroid axis is controlled by the central circadian pacemaker located in the suprachiasmatic nucleus.
- Daily TSH secretion profiles are often disrupted in patients with hypothyroidism or hyperthyroidism.
- Circadian dysfunction caused by shift work, travel across time zones or irregular sleep-wake cycles might be a novel lifestyle risk factor for disturbances in thyroid homeostasis in modern societies.
- Disruption of circadian clock genes *in vivo* and *in vitro* disturb cell cycle progression.
- The circadian clock is thought to be disrupted in well-differentiated thyroid cancer.

Introduction

Thyroid hormones (precursor thyroxine T₄ and active T₃) are iodine containing compounds (iodothyronines) that are important for metabolism, heat production, proper development and differentiation of cells, and growth. Thyroid hormone synthesis and secretion are primarily regulated by TSH, which is derived from thyrotrophs located in the pars distalis in the anterior pituitary gland. TSH production and secretion are regulated by hypothalamic thyrotropin-releasing hormone (TRH). Circulating thyroid hormones control the synthesis and release of TRH and TSH from pars distalis as part of a classic negative-feedback loop called the ‘hypothalamic–pituitary–thyroid (HPT) axis’^{1,2}(FIG. 1).

Organisms are exposed to various rhythmic events, such as daily and seasonal cycles. To better adapt to these cyclic environmental changes, organisms have evolved biological clocks. An approximately 24-h cell-autonomous circadian clock is present in virtually all cells of the body, and this circadian system tightly regulates physiological functions and endocrine rhythms³.

Several lines of evidence indicate that chronic circadian disruption, which can be caused by shift work or travel across time zones, has long-term consequences on human health and increases the risk of weight gain, type 2 diabetes mellitus, cardiovascular disease and several types of cancer⁴⁻⁷. Circadian disruption of the endocrine system is one of the main mechanisms that mediates these circadian-related adverse consequences⁶⁻⁸. Many endocrine factors are known to show time-dependent variations; for example, TSH secretion exhibits a clear daily rhythmicity, and the HPT axis is under circadian control via the central circadian pacemaker in the suprachiasmatic nuclei (SCN) of the anterior hypothalamus⁹.

In this article, we review the interconnection between circadian clocks and thyroid function. We first describe the regulatory mechanisms controlling the HPT axis and provide an overview of the circadian system. We then summarize the current state of knowledge regarding the circadian regulation of the HPT axis. Furthermore, we discuss the connection between disruptions of central and peripheral circadian pacemakers and thyroid function. In addition, we highlight the possible link between thyroid cancer and disrupted circadian machinery.

HPT axis and thyroid hormone activation

In this section, we provide a brief overview of the regulatory mechanism of the HPT axis and highlight the importance of local activation of thyroid hormone. TSH, which is a pituitary-derived hormone that stimulates the thyroid gland to produce T₄ and T₃, is a non-covalently linked heterodimer glycoprotein that consists of α and β subunits. The release of TSH is controlled by the tripeptide hormone TRH (FIG. 1). Derived from a subset of neurons in the paraventricular nucleus of the hypothalamus, TRH is secreted from the hypothalamic median eminence to the anterior pituitary via the hypothalamic–hypophyseal portal system.^{1,2,10}

TRH binds to its membrane receptor on thyrotrophs in the pars distalis of the anterior pituitary and stimulates the synthesis of TSH by inducing mRNA expression of *TSHA* and *TSHB*, which encode the TSH α and β subunits, respectively¹¹. The most sensitive marker of thyroid hormone action are blood levels of TSH, which are elevated in patients with hypothyroidism owing to reduced negative feedback suppression of TRH and TSH. The thyroid gland machinery is stimulated to produce thyroid hormones by TSH binding to the TSH receptor (a G protein-coupled receptor on the thyroid follicle

cell membrane), which in turn stimulates the secondary messengers c AMP and inositol phosphate ¹².

In vertebrates, thyroid hormone is the only hormone that contains iodine. Iodine is taken up from the bloodstream into thyroid follicles. Thyroglobulin, which is a protein that is produced by thyroid epithelial cells, is secreted and stored in the follicular lumen. Thyroglobulin acts as a backbone for tyrosine residues that are subsequently iodinated. After internalization from follicular lumen into follicular cells, iodinated thyroglobulin is degraded through the lysosomal pathway, to release mainly T₄ and some T₃ into the bloodstream. These two iodothyronines circulate, bound reversibly to thyroid hormone-binding proteins: thyroxine-binding globulin, transthyretin, and albumin ². Unbound, also known as 'free', thyroid hormone is transported into target tissues by membrane transporters. The most important membrane transporter for the brain is the monocarboxylate transporter 8 (MCT8) ¹³ and the most important transporters in other tissue are MCT8 and the organic anion transporter polypeptide OATP1C1 ¹⁴.

As the mammalian thyroid gland predominantly produces the hormone precursor, T₄, local activation of thyroid hormone at target tissues is an important mechanism of thyroid hormone action ^{2,15}. Following entry into the cell, thyroid hormone is metabolized by deiodinase enzymes. Type 1 iodothyronine deiodinase (DIO1) and type 2 iodothyronine deiodinase (DIO2) function principally as thyroid hormone activators, generating T₃ from T₄ by removing one iodine from the 5' position of T₄ ¹⁵. They have variable levels of expression in tissues and cell types and in different species; DIO1 is commonly found in liver and kidney, and type 3 iodothyronine deiodinase (DIO3) is normally expressed in the central nervous system and placenta, while DIO2 is more widely expressed in humans. However, unlike humans, rodents express little or no DIO2

in their myocardium ¹⁶.

DIO3 inactivates thyroid hormone by removing iodine from the 5 position of T₄ and T₃, which generates the inactive iodothyronines reverse T₃ and T₂, respectively ¹⁶. Locally generated T₃ is partially released from tissues to the circulation ¹⁶. As thyroid hormones act on nuclear hormone receptors to regulate target gene expression, released T₃ and T₄ act as part of a feedback loop that inhibits the production of hypothalamic-derived TRH and pars distalis-derived TSH (FIG. 1).

The thyroid hormone receptor has isoforms, TR α and TR β . When T₃-bound, these two receptors repress *TRH* and *TSHB* gene expression by binding to some thyroid hormone response elements (sequences containing [A/G]GGT[G/C/A]A) on DNA as either a thyroid hormone receptor monomer, thyroid hormone receptor homodimer, and/or thyroid hormone receptor –retinoid X receptor heterodimer in the *TRH* promoter¹⁷ or the *TSHB* promoter ^{18,19}. In the presence or absence of thyroid hormone, the thyroid hormone receptor complexes regulate positively or negatively target gene expression by interacting with co-activators or co-repressors, respectively ².

Circadian clocks and the master pacemaker

Circadian clocks are highly conserved, endogenous time-keeping mechanisms present in virtually all living organisms. These clocks generate self-sustained oscillations with an approximately 24-h period, referred to as ‘circadian rhythms’ ³. Circadian rhythms modulate multiple physiological and behavioral processes, including sleep–wake cycles, hormone release and metabolism ³.

In mammals, these daily rhythms are primarily controlled by a population of neurons and astrocytes in the SCN, a paired structure located in the anterior hypothalamus

above the optic chiasm^{20,21}. The SCN, which is considered the master pacemaker, receives direct light information from the retina through the retinohypothalamic tract (FIG. 2). Within the retina, intrinsically photosensitive ganglion cells are primarily responsible for ‘circadian photoreception’ and the entrainment of the circadian pacemaker to environmental light–dark cycles^{22,23}, while classical rod and cone photoreceptors have only a supportive role (of note, more than 50% of people who are totally blind have normal entrainment of the circadian pacemaker because their intrinsically photosensitive retinal ganglion cells are intact). Most peripheral tissues and cells also contain self-sustained circadian oscillators that, under normal conditions, are synchronized with the SCN clock via neural and humoral pathways (that is, the autonomous nervous system and the 24-h rhythms of glucocorticoid and melatonin levels)^{3,24,25}.

Molecular mechanisms of the clockwork

The 2017 Nobel Prize for Physiology or Medicine was awarded for the discovery of the molecular mechanism driving circadian rhythms²⁶. Briefly, circadian rhythms are generated by transcription–translation feedback loops consisting of circadian clock genes and proteins²⁷ (FIG. 3). The basic helix-loop-helix proteins circadian locomotor output cycles kaput (CLOCK) and brain and muscle Arnt-like protein 1 (BMAL1) heterodimerize to form a transcriptional activator complex and activate the period (*PER*) and cryptochrome (*CRY*) repressor genes through E-box (CACGTG) enhancers, whose protein products in turn repress their own transcription^{28,29}. The CLOCK–BMAL1 heterodimer also induces reverse strand of ERB α (REV-ERB α) and REV-ERB β , and retinoic acid receptor-related orphan receptor- α (ROR α), ROR β and ROR γ , which regulate *CLOCK* and *BMAL1* genes through ROR elements but exert opposite effects on

gene transcription, thus constituting a second important interlocking feedback loop^{30–32} (FIG. 3).

The transcription–translation feedback loops of circadian clock genes drive rhythmic expression of many clock-controlled genes. The latter represent between 3% and 16% of the transcriptome in a given tissue³³. As clock-controlled genes include genes that modulate transcription, signal transduction, protein turnover and metabolism, the circadian clocks influence various cellular, organ and physiological functions in a manner that depends on the time of day.

Circadian regulation of the HPT axis

Evidence of TSH rhythms.

In this section we describe how the internal circadian clock regulates the mammalian HPT axis and thyroid function. As is the case for other pituitary hormones, TSH secretion is partly controlled by the central circadian pacemaker in the SCN^{34,35} (FIG. 2). In humans, circulating TSH levels exhibit a clear daily rhythm. Plasma concentrations begin to rise in the late afternoon or early evening before sleep onset, and reach maximal levels during the early part of the night. Following the nighttime peak in TSH, plasma TSH concentration then declines during the rest of the sleep period until reaching low daytime levels.

Multiple studies that examined sleep deprivation and acute shifts of the sleep period have reported that TSH release into the blood is inhibited during sleep^{36,37}. The interaction between the circadian-controlled nocturnal rise in TSH and the inhibitory effect of sleep is illustrated in the lower panel in FIG. 4, which shows the mean profile of plasma TSH levels in healthy young men who were sampled at 20-min intervals over

a 53-h period, including an 8-h period of ‘normal’ average night sleep, a night of total sleep deprivation and an 8-h period of daytime recovery sleep³⁶. TSH release, which is normally inhibited during sleep, continues to occur during nocturnal sleep deprivation. Therefore, morning plasma TSH levels are roughly twice as high in humans who have had a sleepless night than in humans who have had a night of normal sleep³⁶.

The upper panel in **FIG. 4** illustrates a representative individual plasma TSH profile. It shows that a low amplitude **ultradian** rhythm of TSH is also present in humans, which reflects the pulsatile release of the hormone^{34,38} (**Table 1**). This ultradian rhythm seems to be influenced by the sleep stage such as the slow-wave sleep³⁸ and food intake³⁹. Thyroid hormone and glucocorticoid have also been to modulate the pulsatile secretion of TSH in healthy men⁴⁰.

Mechanisms.

The mechanisms generating ultradian TSH rhythms are still unclear^{41,42}. Several studies have reported no intergender differences in circadian and ultradian TSH release patterns^{43,44}; however, a paper from 2015 based on 324,750 outpatients with no known thyroid disease found that females have higher plasma TSH levels than males⁴⁵.

In addition to the well-characterized rhythm in plasma levels of TSH, daily variations in plasma thyroid hormone levels have also been reported in the humans and in wild-type rats^{46,47}. Some studies, however, have not detected these variations^{48,49}. This discrepancy is thought to result from differences in experimental conditions and analytical tools between research groups⁵⁰. It should also be noted that nocturnal rodents might not be an ideal model to explore the mechanisms underlying the human temporal control of TSH and thyroid hormone release. The reason that laboratory rodents are not an ideal

model is because they undergo multiphasic sleep during the light phase whereas humans have a consolidated nocturnal sleep period.

Neural projections from the SCN to TRH neurons in the paraventricular nucleus form the anatomical basis for the daily rhythms in TRH synthesis and secretion, and thus are responsible for rhythmic TSH secretion from the pars distalis^{9,51–53} (**FIG. 2**). Indeed, in rats, an SCN lesion abolishes the rhythmicity of circulating TSH and thyroid hormones, which suggests that the SCN is involved in the regulation of the HPT axis^{53,54} (**Table 1**); however, peripheral clocks can also regulate rhythmic transcription of genes that regulate hormone secretion, for example, human growth hormone (*GH*)⁵⁵. Indeed, in the mouse TαT1.1 thyrotroph cell line, the circadian rhythmicity of *Tshb* expression is regulated by the local circadian clock (REV-ERBα) along with the Tr complex co-activator nuclear receptor corepressor 1 (NCOR1)⁵⁶ (**Table 1**). Of note, however, hypophysectomy extinguishes the rhythmicity of circulating thyroid hormone levels, but not the rhythmicity of circadian clock genes (*Per1* and *Bmal1*) in rat thyroid⁵⁷. These data suggest that the daily rhythm of thyroid hormone release from the thyroid gland is regulated by the central circadian pacemaker in the SCN via rhythmic TSH secretion, rather than by the local circadian clock in the thyroid gland.

Some studies have demonstrated that genes encoding thyroid hormone receptors exhibit rhythmic expression in mouse white adipose tissue (*Thra* and *Thrb*), brown adipose tissue (*Thra*), kidney (*Thra*), and liver (*Thra*)^{58–60}. Furthermore, real-time qPCR has shown rhythmic expression of thyroid hormone receptors in rat liver (*Thra* and *Thrb*)⁵⁴. A lesion study in rats showed that the rhythmic expression of liver TRα is regulated by the SCN, whereas that of TRβ is affected by food intake⁵⁴. Interestingly, in humans, mice and rats, the *Thra* overlaps with *Rev-erba*, which is on the opposite DNA

strand ⁶¹. This finding lead to the speculation that circadian *Thra* expression is mediated by an antisense mechanism ⁶¹; however, strand-specific RNA-sequencing revealed that *Thra* does not show a clear oscillation in mouse liver ⁶². Arrhythmic expression of both *Thr* genes has also been reported in mouse skeletal muscle ⁵⁸. These discrepancies could be due to tissue-specific expression patterns or the analytical methods used.

Circadian rhythms in thyroid diseases

In the previous section, we described the link between circadian clocks and thyroid function. Here we consider the relationship between circadian rhythms and thyroid diseases, specifically hypothyroidism and hyperthyroidism.

Hypothyroidism.

A reduced production of thyroid hormones is the central feature of hypothyroidism. Loss of the thyroid gland function through a destructive processes including autoimmunity (Hashimoto disease), irradiation, or surgical ablation, and congenital defects in hormone synthesis or gland development are termed ‘primary hypothyroidism’. Central hypothyroidism is caused by dysfunction of the pituitary (secondary hypothyroidism) or the hypothalamus (tertiary hypothyroidism). Defects or damage to brain regions results in insufficient stimulation of the normal thyroid gland. Approximately 99.9% of cases of hypothyroidism are caused by primary hypothyroidism, but it depends on age ^{63,64}.

The term ‘subclinical hypothyroidism’ is applied to primary hypothyroidism when TSH is high but free T₄ is still in the normal range. In this form of mild hypothyroidism, total TSH secretion is increased above the upper limit of normal while in severe hypothyroidism the increase could be as high as ~200-fold ⁶⁵. The daily TSH secretion

pattern is sustained in mild hypothyroidism, but markedly high serum TSH levels in severe cases obliterate the detection of rhythmicity^{66,67}. A study from 2016 revealed higher serum TSH levels and an elevated risk of subclinical hypothyroidism in night shift workers than non-night shift workers⁶⁸ (FIG. 5a). However, because the authors of this study measured serum TSH levels at only one time point during the day, careful evaluation is necessary as this alteration could be caused by a phase shift of the TSH rhythm. Autoimmune thyroid disorders are also associated with shift work⁶⁹.

In central hypothyroidism caused by inactivating mutations in TRH and TRH receptor, serum TSH concentration is within subnormal or mildly increased levels⁷⁰. In such cases, however, circulating T₄ levels are diminished. Cranial irradiation therapy for brain tumors and leukemia also cause abnormal TRH secretion patterns, leading to disrupted or absent TSH rhythm⁷¹. Glycosylation influences the bioactivity and half-life of glycoprotein hormones⁷², and the pars distalis TSH glycans are mainly biantennary and sulfated complexes⁷³. Diminished T₄ levels accompanied by elevated or normal TSH levels in central hypothyroidism are caused by a reduction in the bioactivity of TSH due to increased sialylation of glycan⁷⁴. As TRH regulates sulfation and sialylation of TSH glycan⁷⁵, TRH deficiency also induces abnormal glycosylation of TSH, resulting in loss of the normal circadian pattern of TSH secretion^{71,76}.

Defects in thyroid hormone receptors cause reduced sensitivity to the hormone⁷⁷. In patients with a mutation in *THRB*, elevated serum T₄ and T₃ and slightly elevated or normal TSH are observed due to a reduced negative feedback of the HPT axis⁷⁷. Enlargement of the thyroid gland and increased synthesis of thyroid hormone result from an increase in TSH bioactivity⁷⁸. In most patients, basal serum TSH concentration is normal and the circadian rhythm is preserved⁷⁹.

Decreased sensitivity to thyroid hormone caused by THRA mutations manifests in affected tissues expressing mainly the THRA gene ⁸⁰. The clinical features of such patients are dysmorphic features, skeletal dysplasia, growth retardation and intellectual deficit ⁸⁰. The associated biochemical abnormalities include low or low to normal T₄ concentrations and high or high to normal T₃ concentrations ⁸⁰.

Hyperthyroidism.

In marked contrast to hypothyroidism, hyperthyroidism is characterized by excessive quantities of thyroid hormones in the presence of normal thyroid hormone receptor expression ⁵⁰. Common conditions causing hyperthyroidism include overstimulation of the thyroid gland by immunoglobulins that bind to the TSH receptor, activating mutations of the TSH receptor and (although rarely) TSH producing pituitary tumors ⁵⁰. Circadian rhythmicity of serum TSH levels in hyperthyroidism is not expected as TSH is suppressed and diurnal rhythm of thyroid hormone does not occur because hormone synthesis and secretion is under the control of immunoglobulins ⁸¹. In rare instances of hyperthyroidism that result from TSH producing pituitary adenomas, the TSH secretion pattern is more irregular, but the diurnal rhythm is preserved ⁸².

Thyroid hormone and gene expression

Next, we describe how thyroid hormone deficiency and excess affect the circadian clock. When wheel running activity rhythms were studied under constant condition, surgical removal of the thyroid and parathyroid glands shortens the period of circadian activity rhythms in rats ^{83,84}, and thiourea and thyroxine administration lengthens the period of circadian activity rhythms in hamsters and rats ^{84,85} (**Table 2**). However, as knocking out

Thrb does not directly alter the circadian behaviour of mice ⁸⁶, effects of thyroid hormones on circadian behaviour might be mediated by *Trα*. It is interesting to note that *Trα* is predominantly expressed in the heart ⁸⁷.

In rats, the expression patterns of circadian clock genes (*Per2*, *Bmal1*, *Rev-erba*, and *Rora*) and clock-controlled genes (*Pdk4* and *Ucp3*) in the heart are affected by hyperthyroidism and hypothyroidism, which suggests that chronic alterations in thyroid status affect the circadian clock and metabolic function in this organ ⁸⁸(**Table 2**). In the rat brain, thyroidectomy affects the expression of PER2 in the bed nucleus of the stria terminalis, as well as the amygdala, while it does not affect the SCN clock ⁸⁹(**Table 2**). Moreover, co-culture with thyroid gland does not modulate the circadian rhythms of Rat-1 fibroblasts ⁹⁰. These data indicate that abnormal serum levels of thyroid hormone affects the circadian clocks in peripheral tissues, which might be dependent on tissue-specific thyroid hormone receptor regulation.

The circadian clock and tumorigenesis

In this section, we describe the molecular link between circadian clocks and cancer. Disruption of the circadian clocks due to shift work or travel across time zones leads to circadian desynchrony, or jet lag, which reflects a mismatch between the internal biological clock and external time cues ⁹¹ (**BOX 1; FIG. 5a**).

Chronic circadian disruption has long-term consequences on our health and increases the risk of cancers in the immune, skeletal, digestive and reproductive organs that require cell proliferation, metabolism, and DNA damage repair to maintain daily function ⁷. In fact, variants of various clock genes (*PER1*, *PER2* and *PER3*, and *CRY1* and *CRY2*, in addition to *REV-ERB* genes and *ROR* genes) are associated with thyroid

cancer in humans ⁷. Circadian disruption also affects endocrine functions, including glucocorticoid, melatonin, and pituitary hormone) ⁸. Specifically, in the HPT axis, disruption of plasma levels of TSH and T₃ have been observed in shift work, jet lag and chronic sleep debt in humans ^{37,68,92,93} (**Table 1; FIG. 5b**). The normal evening rise of plasma levels of TSH is decreased or absent in human in a sleep debt condition achieved by bedtime restriction for 4 h for six nights compared with a fully rested condition (allowed 12 h in bed per night for six nights) ³⁷ (**Table 1; FIG. 5b**).

Because chronic circadian disruption has long-term consequences on our health ⁷, it is necessary to evaluate the effects of long-term circadian and sleep disruption on the HPT axis. Some studies suggest that elevated concentrations of serum TSH is linked to the incidence of human thyroid cancer ⁹⁴⁻⁹⁶; however, it is not clear if this is causative or the consequence of the cancer. Furthermore, two 2018 cohort studies that investigated circadian disruption in flight attendants and flight crews did not provide convincing evidence of an association with elevated risk of thyroid cancers ^{97,98}. Therefore, further studies are indeed required to clarify the relationship between circadian disruption and thyroid cancer further studies are indeed required to clarify the relationship between circadian disruption and thyroid cancer.

Loss of cell cycle regulation also leads to the development of cancer ⁹⁹⁻¹⁰¹. It remains unclear whether, and if so to what extent, circadian clocks are involved in this process; however, synchronization of circadian clock function in tumor cells impinges on the cell cycle and suppresses cellular growth ⁹⁹. Emerging evidence suggests molecular connections between the circadian clock and cell cycle regulators, such as Wee1 (which inhibits the G2/M transition by phosphorylation of CDK1), and Cyclin B1

(Ccnb1) in melanoma cells. For example, Clock/Bmal1 activates *Wee1* in mouse liver, and PER influences the transcription of *WEE1* and *CCNB1* in human cancer cell ^{100,101}.

PER1 and PER2 are necessary for transcriptional activation of cell cycle checkpoint genes in several mouse tissues ¹⁰². *Bmal1* positively regulates the p53 tumor suppressor pathway and has anti-tumor activity in human pancreatic cancer ¹⁰³. Genetic manipulations in mice have demonstrated the direct relationship between tumor and clock genes through activation of cell cycle in spontaneous and radiation-induced tumor development in liver, ovary, kidney ¹⁰⁴, lymphoid tissue ¹⁰⁵ and lung ¹⁰⁶. In the case of thyroid cancer, increased expression of the circadian clock component DEC1 (differentially expressed in chondrocytes 1), which targets the E-box, is reported to drive the expression of many cell cycle-related genes and promotes thyroid cancer in humans ¹⁰⁷(Table 1).

Circadian clocks in thyroid nodules and thyroid cancer.

In this section, we explore the potential link between circadian clocks and the development of thyroid cancer. Although the aforementioned studies suggest that there could be a causal link from disruption of the circadian system to cancer, other studies have established a link in the opposite direction ^{108,109}. Multiple aspects of tumours, including the *RAS* and *MYC* oncogenes, can induce dysregulation of circadian clocks in human cancer cell lines ^{108,109}. While it remains unclear whether the circadian clock is actually disrupted within human tumors *in vivo*, it is important to characterize the profiles of clock disruption in human cancers in order to develop novel anti-tumor strategies.

Thyroid nodules, defined as any discrete mass in the thyroid gland, can often represent an abnormal growth of thyroid cells in discrete regions within the thyroid gland,

are often detected in humans, but most are non-cancerous (benign) ¹¹⁰. Well-differentiated thyroid cancer constitutes the vast majority (more than 90%) of all thyroid cancers ^{111,112}. Poorly differentiated thyroid carcinoma is less common than well-differentiated thyroid cancer but is more aggressive ^{111,112}. Robust circadian oscillation of clock genes has been observed in primary cultured thyrocytes established from healthy human thyroid tissue and benign nodules ¹¹³; however, the up-regulation of *BMAL1* and down-regulation of *CRY2* have been detected in tissue samples from well-differentiated thyroid cancer, and dramatic changes in circadian clock genes expression has been reported in poorly differentiated thyroid carcinoma ¹¹³. Therefore, it is hypothesized that the circadian clock machinery in the thyroid could be altered during malignant transformation ¹¹³ (**Table 2**). Thyroid nodules are detected in up to 65% of the general populations and are usually benign ¹¹⁰. Mutational analysis and gene expression analyses are two common molecular tests for malignancy. Mutational analysis involves sequencing specific proto-oncogenes, such as *BRAF* and *RAS*, for possible mutations. In contrast, gene expression analysis examines specific gene sets, called ‘gene expression classifiers’. However, because of the low positive predictive value, refinement in molecular testing strategies with improved diagnostic performance is required ¹¹⁰. As alterations in the clock machinery are observed in malignant transformation of thyroid nodules, it is hypothesized that characterization of circadian clock genes expression might help improve pre-operative diagnosis of thyroid nodules. This hypothesis should be addressed in future studies.

Seasonal rhythms and thyroid function

In addition to circadian rhythms, thyroid function is intimately linked to seasonal rhythms. In this section we discuss the link between seasonal rhythms and thyroid function. Most

animals exhibit seasonal changes in physiology and behaviour, such as reproduction, migration and hibernation, in order to adapt to seasonal changes in environment ¹¹⁴. In rats and hamsters, the circadian rhythms of levels of TSH and thyroid hormones in the blood exhibit seasonal changes ^{115,116}.

Seasonality has also been reported in humans, including alterations in mood, immune function, duration and amplitude of melatonin secretion, endocrine function and gene expression ^{117,118}. Some studies in humans reported that levels of thyroid hormone in the circulation decrease during the summer ^{119,120}. Although several studies have demonstrated that humans exhibit seasonality in circulating levels of TSH ^{119,121}, other cohort studies have argued that TSH has little seasonality ^{45,122}. In thyrotoxicosis, the peak incidence of diagnosis of hyperthyroidism probably occurs during the summer because the symptoms of heat intolerance in patients with hyperthyroidism are more noticeable during the summer period ¹²³. Thyroid cancers exhibit an annual rhythm, with markedly more patients presenting with the disease during the late autumn and winter ¹²⁴. The underlying mechanisms of seasonal regulation of these thyroid diseases remains to be elucidated.

Seasonal reproduction of animals ensures the survival of offspring. A 2008 functional genomic analysis of seasonal breeding animals revealed unexpected roles of TSH and thyroid hormone in the regulation of seasonality ¹²⁵. Long-day stimulus induces TSH production in the pars tuberalis of the pituitary gland in birds ¹²⁵. TSH derived from the pars tuberalis acts on the hypothalamus to induce *DIO2* and downregulate *DIO3* ¹²⁵ (**FIG. 6**). The switch from *DIO2* to *DIO3* fine-tunes local bioactive thyroid hormone concentrations within the hypothalamus, which in turn regulates seasonal reproduction in birds and mammals ¹²⁶⁻¹²⁹. Thyrotrophs in the pars tuberalis lack TRH receptors and

thyroid hormone receptors, which makes pars tuberalis-derived TSH independent from the HPT axis in mammals ^{73,130}.

The hormone melatonin, which is released by the pineal gland, provides an endocrine representation of seasonal information (such as changes in day length) via the SCN–pineal pathway in mammals ¹³¹. Studies using knockout mice revealed that thyrotrophs in the pars tuberalis are the targets of nocturnal melatonin; specifically, pars tuberalis-derived TSH is negatively regulated by melatonin via the MT1 melatonin receptor ^{128,132} (**FIG. 6**). A 2014 murine study revealed that pars tuberalis TSH is secreted into the circulation at a level similar to pars distalis-derived TSH, but has minimal effects on the thyroid gland ⁷³ (**BOX 2; FIG. 6**). Hibernation in mammals, including primates and rodents, is also an important adaptation strategy ^{133,134}. A 2018 study in hamsters demonstrated that *Dio2* expression is decreased in the brown adipose tissue during hibernation ¹³⁵, suggesting important roles for thyroid hormone in various seasonal adaptation mechanisms.

Future directions

The precise role of circadian clocks in thyroid function and diseases needs to be addressed in future studies. Thyroid-specific conditional knockout of circadian clock genes and/or circadian clock manipulation within the functional thyroid tissue derived from embryonic or pluripotent stem cells would provide an opportunity to test the link between circadian clock and thyroid function and disease¹³⁶.

The disruption of circadian clocks has been implicated in various diseases, and accordingly the identification of circadian clock modulators might provide new opportunities for treatment of clock-related disorders ¹³⁷. Studies from 2018 and 2019

have demonstrated that agonists of the REV-ERB proteins are specifically lethal to cancer cells and that a selective CK2 inhibitor inhibits cancer cell growth^{138,139}. Therefore, pharmacological modulation of the circadian machinery may be an innovative and selective strategy for treating a wide spectrum of cancers, including thyroid cancer¹³⁹.

Conclusions

To better adapt to daily environmental changes, animals have evolved circadian clock for the regulation of various physiological and endocrine rhythms³. The HPT axis is controlled by the circadian system, with a predominant role for the central pacemaker in the SCN, as well as the sleep-wake cycle^{34,35,53,54}. Thyroid status such as hypothyroidism, hyperthyroidism, and thyroid cancer affects peripheral circadian clocks⁸³⁻⁹⁰. Thus, thyroid function and circadian clocks are interconnected. Epidemiologic studies have suggested that chronic circadian disruption has long-term consequences on our health and is an important lifestyle factor that contributes to the risk of developing obesity, diabetes, cancer, and cardiovascular disease⁴⁻⁷. Indeed, chronic sleep dept disrupts rhythmic TSH secretion³⁷. Generalized disruption of the endocrine system is one of the important mechanisms thought to mediate the adverse effects of circadian misalignment⁶⁻⁸. Although several studies suggested that elevated serum TSH level is linked to the incidence of human thyroid cancer⁹⁴⁻⁹⁶, relationship between circadian disruption and thyroid cancer require further investigation. By contrast, perturbation of oncogene can induce dysregulation of circadian clock^{108,109} and disrupted circadian clock gene expression is reported during thyroid nodule malignant transformation¹¹³. Since disruption of circadian clocks has been implicated in various diseases¹³⁷, pharmacological modulation of the circadian clock machinery might provide a new

strategy for the treatment of thyroid diseases ¹³⁹.

Box 1. Central clock versus peripheral clocks

The mammalian circadian system is comprised of the central master pacemaker located in the hypothalamic suprachiasmatic nucleus (SCN) and a multitude of peripheral circadian clocks that use the same molecular machinery as the SCN clock and receive synchronizing inputs from the central clock. When disconnected from the central clock, the peripheral clocks are capable of generating self-sustained circadian oscillations under constant environmental conditions for at least a few cycles²⁵. Circadian misalignment occurs when the central clock is not aligned with the peripheral clocks and/or when distinct peripheral clocks are not in synchrony with each other⁹¹. Circadian misalignment can happen when a stimulus that affects a peripheral tissue (such as the feeding schedule for the liver) does not affect another peripheral tissue (for example, those that are not sensitive or less sensitive to dietary cues)³.

Box 2. Pars tuberalis TSH and macro-TSH

TSH is a glycoprotein⁷². A 2014 study in mice revealed that TSH derived from pars tuberalis is secreted into the circulation but has little bioactivity in the thyroid gland⁷³. TSH from the pars tuberalis has decreased bioactivity because it forms macro-TSH complexes with immunoglobulin (IgG) and albumin in the circulation⁷³. These complexes form as the result of differences in *N*-glycosylation patterns between TSH derived from the pars tuberalis (with sialylated multibranched *N*-glycans) and TSH derived from the pars distalis (with sulfated bi-antennary *N*-glycans)⁷³ (**FIG. 6**). Therefore, tissue-specific glycosylation of TSH in the pars tuberalis and pars distalis compartmentalizes TSH function, thereby preventing functional crosstalk within the body.

These tissue-specific features of glycosylation seem to be due to tissue-specific expression of glycosyltransferases ⁷³.

In humans, primary or central hypothyroidism and hyperthyroidism are sometimes associated with high serum levels of macro-TSH complex (that is, high molecular weight TSH-IgG complex with reduced bioactivity) ¹⁴⁰⁻¹⁴². However, high serum levels of TSH that result from the presence of macro-TSH complex are found in the absence of thyroid dysfunction and in the presence of normal thyroid hormone levels, although the underlying mechanism for this remains unclear ^{143,144}. The dynamics of circulating TSH in individuals with high TSH but without thyroid dysfunction are similar to those of TSH that is derived from pars tuberalis. That is, the circulating TSH in these individuals has sialylated multibranched *N*-glycans with low bioactivity and a long half-life ^{74,75,141,142,145}. Although seasonality has been reported in many human functions, such as mood, immune function, metabolism and hormone secretion, their underlying mechanisms remain unknown ^{117,118}. Therefore, the functional significance of human TSH derived from the pars tuberalis is of interest ¹⁴⁶.

References

1. Fekete, C. & Lechan, R. M. Central regulation of hypothalamic-pituitary-thyroid axis under physiological and pathophysiological conditions. *Endocr. Rev.* **35**, 159–194 (2014).
2. Ortiga-Carvalho, T. M., Chiamolera, M. I., Pazos-Moura, C. C. & Wondisford, F. E. Hypothalamus-pituitary-thyroid axis. *Compr. Physiol.* **6**, 1387–1428 (2016).
3. Mohawk, J. A., Green, C. B. & Takahashi, J. S. Central and peripheral circadian clocks in mammals. *Annu. Rev. Neurosci.* **35**, 445–462 (2012).
4. Scheer, F. A. J. L., Hilton, M. F., Mantzoros, C. S. & Shea, S. A. Adverse metabolic and cardiovascular consequences of circadian misalignment. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 4453–4458 (2009).
5. Davidson, A. J. *et al.* Chronic jet-lag increases mortality in aged mice. *Curr. Biol.* **16**, 914–916 (2006).
6. Buxton, O. M. *et al.* Adverse metabolic consequences in humans of prolonged sleep restriction combined with circadian disruption. *Sci. Transl. Med.* **4**, 129ra43 (2012).
7. Kettner, N. M., Katchy, C. A. & Fu, L. Circadian gene variants in cancer. *Ann. Med.* **46**, 208–220 (2014).
8. Bellastella, A. *et al.* Endocrine secretions under abnormal light-dark cycles and in the blind. *Horm. Res.* **49**, 153–157 (1998).
9. Kalsbeek, A. & Fliers, E. Daily regulation of hormone profile. in *Handbook of experimental pharmacology* (eds. Kramer, A. & Meroz, M.) **217**, 185–226 (Springer Berlin Heidelberg, 2013).
10. Pierce, J. G. Eli Lilly lecture: The subunits of pituitary thyrotropin—their relationship to other glycoprotein hormones. *Endocrinology* **89**, 1331–1344 (1971).
11. Shupnik, M. A., Greenspan, S. L. & Ridgway, E. C. Transcriptional regulation of thyrotropin subunit genes by thyrotropin-releasing hormone and dopamine in pituitary cell culture. *J. Biol. Chem.* **261**, 12675–12679 (1986).
12. Vassart, G. & Dumont, J. E. The thyrotropin receptor and the regulation of thyrocyte function and growth. *Endocrine Reviews* **13**, 596–611 (1992).
13. Friesema, E. C. H. *et al.* Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. *J. Biol. Chem.* **278**, 40128–40135 (2003).
14. Pizzagalli, F. *et al.* Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. *Mol. Endocrinol.* **16**, 2283–2296 (2002).

15. Schweizer, U., Weitzel, J. M. & Schomburg, L. Think globally: Act locally. New insights into the local regulation of thyroid hormone availability challenge long accepted dogmas. *Mol. Cell. Endocrinol.* **289**, 1–9 (2008).
16. Gereben, B. *et al.* Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. *Endocr. Rev.* **29**, 898–938 (2008).
17. Hollenberg, A. N. *et al.* The human thyrotropin-releasing hormone gene is regulated by thyroid hormone through two distinct classes of negative thyroid hormone response elements. *Mol. Endocrinol.* **9**, 540–550 (1995).
18. Franklyn, J. A., Wood, D. F., Balfour, N. J. & Sheppard, M. C. Effect of triiodothyronine treatment on thyrotrophin β - and α -messenger RNAs in the pituitary of the euthyroid rat. *Mol. Cell. Endocrinol.* **60**, 1–5 (1988).
19. Cohen, O., Flynn, T. R. & Wondisford, F. E. Ligand-dependent antagonism by retinoid X receptors of inhibitory thyroid hormone response elements. *J. Biol. Chem.* **270**, 13899–13905 (1995).
20. Ralph, M. R., Foster, R. G., Davis, F. C. & Menaker, M. Transplanted suprachiasmatic nucleus determines circadian period. *Science* **247**, 975–978 (1990).
21. Brancaccio, M. *et al.* Cell-autonomous clock of astrocytes drives circadian behavior in mammals. *Science* **192**, 187–192 (2019).
22. Panda, S. *et al.* Melanopsin is required for non-image-forming photic responses in blind mice. *Science* **301**, 525–527 (2003).
23. Hattar, S. *et al.* Melanopsin and rod-cone photoreceptive systems account for all major accessory visual functions in mice. *Nature* **424**, 76–81 (2003).
24. Balsalobre, A., Damiola, F. & Schibler, U. A serum shock induces circadian gene expression in mammalian tissue culture cells. *Cell* **93**, 929–937 (1998).
25. Yamazaki, S. *et al.* Resetting central and peripheral circadian oscillators in transgenic rats. *Science* **288**, 682–685 (2000).
26. Sehgal, A. Physiology flies with time. *Cell* **171**, 1232–1235 (2017).
27. Takahashi, J. S. Molecular components of the circadian clock in mammals. *Diabetes, Obes. Metab.* **17**, 6–11 (2015).
28. Gekakis, N. *et al.* Role of the CLOCK protein in the mammalian circadian mechanism. *Science* **280**, 1564–1569 (1998).
29. Hogenesch, J. B., Gu, Y.-Z., Jain, S. & Bradfield, C. A. The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors. *Proc. Natl. Acad. Sci. U. S. A.* **95**, 5474–5479 (1998).
30. Cho, H. *et al.* Regulation of circadian behaviour and metabolism by REV-ERB- α

- and REV-ERB- β . *Nature* **485**, 123–127 (2012).
31. Ueda, H. R. *et al.* A transcription factor response element for gene expression during circadian night. *Nature* **418**, 534–539 (2002).
 32. Preitner, N. *et al.* The orphan nuclear receptor REV-ERB α controls circadian transcription within the positive limb of the mammalian circadian oscillator. *Cell* **110**, 251–260 (2002).
 33. Zhang, R., Lahens, N. F., Ballance, H. I., Hughes, M. E. & Hogenesch, J. B. A circadian gene expression atlas in mammals: Implications for biology and medicine. *Proc. Natl. Acad. Sci. U. S. A.* **111**, 16219–16224 (2014).
 34. Weeke, J. & Gundersen, H. J. Circadian and 30 minutes variations in serum TSH and thyroid hormones in normal subjects. *Acta. Endocrinol. (Copenh)* **89**, 659–672 (1978).
 35. Copinschi, G. & Challet, E. Endocrine rhythms, the sleep-wake cycle, and biological clocks. in *Endocrinology: Adult and Pediatric* (eds. Jameson, J. L. & Groot, L. De) 147-173.e9 (Elsevier, 2016).
 36. Van Cauter, E. & Spiegel, K. Circadian and sleep control of hormonal secretions. in *Regulation of sleep and circadian rhythms* (eds. Turek, F. W. & Zee, P. C.) 397–426 (Marcel Dekker, Inc., 1999).
 37. Spiegel, K., Leproult, R. & Van Cauter, E. Impact of sleep debt on metabolic and endocrine function. *Lancet* **354**, 1435–1439 (1999).
 38. Gronfier, C. & Brandenberger, G. Ultradian rhythms in pituitary and adrenal hormones: Their relations to sleep. *Sleep Med. Rev.* **2**, 17–29 (1998).
 39. Romijn, J. A. *et al.* Pulsatile secretion of thyrotropin during fasting: A decrease of thyrotropin pulse amplitude. *J. Clin. Endocrinol. Metab.* **70**, 1631–1636 (1990).
 40. Brabant, G. *et al.* Circadian and pulsatile thyrotropin secretion in euthyroid man under the influence of thyroid hormone and glucocorticoid administration. *J. Clin. Endocrinol. Metab.* **65**, 83–88 (1987).
 41. Samuels, M. H., Veldhuis, J. D., Henry, P. & Ridgway, E. C. Pathophysiology of pulsatile and copulsatile release of thyroid-stimulating hormone, luteinizing hormone, follicle-stimulating hormone, and α -Subunit. *J. Clin. Endocrinol. Metab.* **71**, 425–432 (1990).
 42. Samuels, M. H., Henry, P., Luther, M. & Ridgway, E. C. Pulsatile TSH secretion during 48-hour continuous TRH infusions. *Thyroid* **3**, 201–206 (1993).
 43. Brabant, G. *et al.* Physiological regulation of circadian and pulsatile thyrotropin secretion in normal man and woman. *J. Clin. Endocrinol. Metab.* **70**, 403–409

- (1990).
44. Roelfsema, F. *et al.* Thyrotropin secretion profiles are not different in men and women. *J. Clin. Endocrinol. Metab.* **94**, 3964–3967 (2009).
 45. Ehrenkranz, J. *et al.* Circadian and circannual rhythms in thyroid hormones: determining the TSH and free T₄ reference intervals based upon time of day, age, and sex. *Thyroid* **25**, 954–961 (2015).
 46. Lucke, C., Hehrmann, R., von Mayersbach, K. & von zur Muhlen, A. Studies on circadian variations of plasma TSH, thyroxine and triiodothyronine in man. *Acta Endocrinol.* **86**, 81–88 (1977).
 47. Jordan, D., Rousset, B., Perrin, F., Fournier, M. & Orgiazzi, J. Evidence for circadian variations in serum thyrotropin, 3,5,3'-triiodothyronine, and thyroxine in the rat. *Endocrinology* **107**, 1245–1248 (1980).
 48. Fukuda, H. *et al.* Nyctohemeral and sex-related variations in plasma thyrotropin, thyroxine, and triiodothyronine. *Endocrinology* **97**, 1424–1431 (1975).
 49. Azukizawa, M., Eugene Pekary, A., Hershman, J. M. & Parker, D. C. Plasma thyrotropin, thyroxine, and triiodothyronine relationships in man. *J. Clin. Endocrinol. Metab.* **43**, 533–542 (1976).
 50. Roelfsema, F. & Veldhuis, J. D. Thyrotropin secretion patterns in health and disease. *Endocr. Rev.* **34**, 619–657 (2013).
 51. Mazzocchi, G. *et al.* The hypothalamic-pituitary-thyroid axis and melatonin: Possible interactions in the control of body temperature. *Neuroendocrinol. Lett.* **25**, 368–372 (2004).
 52. Covarrubias, L. *et al.* In vitro TRH release from hypothalamus slices varies during the diurnal cycle. *Neurochem. Res.* **19**, 845–850 (1994).
 53. Kalsbeek, A., Fliers, E., Franke, A. N., Wortel, J. & Buijs, R. M. Functional connections between the suprachiasmatic nucleus and the thyroid gland as revealed by lesioning and viral tracing techniques in the rat. *Endocrinology* **141**, 3832–3841 (2000).
 54. Zandieh Doulabi, B. *et al.* Diurnal variation in rat liver thyroid hormone receptor (TR)- α messenger ribonucleic acid (mRNA) is dependent on the biological clock in the suprachiasmatic nucleus, whereas diurnal variation of TR β 1 mRNA is modified by food intake. *Endocrinology* **145**, 1284–1289 (2004).
 55. Vakili, H., Jin, Y. & Cattini, P. A. Evidence for a circadian effect on the reduction of human growth hormone gene expression in response to excess caloric intake. *J. Biol. Chem.* **291**, 13823–13833 (2016).
 56. Aninye, I. O., Matsumoto, S., Sidhaye, A. R. & Wondisford, F. E. Circadian

- regulation of *Tshb* gene expression by Rev-Erb α (NR1D1) and nuclear corepressor 1 (NCOR1). *J. Biol. Chem.* **289**, 17070–17077 (2014).
57. Fahrenkrug, J., Georg, B., Hannibal, J. & Jørgensen, H. L. Hypophysectomy abolishes rhythms in rat thyroid hormones but not in the thyroid clock. *J. Endocrinol.* **233**, 209–216 (2017).
 58. Yang, X. *et al.* Nuclear receptor expression links the circadian clock to metabolism. *Cell* **126**, 801–810 (2006).
 59. Hatanaka, F. *et al.* Genome-wide profiling of the core clock protein BMAL1 targets reveals a strict relationship with metabolism. *Mol. Cell. Biol.* **30**, 5636–5648 (2010).
 60. Nikolaeva, S. *et al.* The circadian clock modulates renal sodium handling. *J. Am. Soc. Nephrol.* **23**, 1019–1026 (2012).
 61. Munroe, S. H. & Lazar, M. A. Inhibition of c-erbA mRNA splicing by a naturally occurring antisense RNA. *J. Biol. Chem.* **266**, 22083–22086 (1991).
 62. Vollmers, C. *et al.* Circadian oscillations of protein-coding and regulatory RNAs in a highly dynamic mammalian liver epigenome. *Cell Metab.* **16**, 833–845 (2012).
 63. Benvenga, S., Klose, M., Vita, R. & Feldt-Rasmussen, U. Less known aspects of central hypothyroidism: Part 2 – Congenital etiologies. *J. Clin. Transl. Endocrinol.* **14**, 5–11 (2018).
 64. Benvenga, S., Klose, M., Vita, R. & Feldt-Rasmussen, U. Less known aspects of central hypothyroidism: Part 1 – Acquired etiologies. *J. Clin. Transl. Endocrinol.* **14**, 25–33 (2018).
 65. Biondi, B. & Cooper, D. S. The clinical significance of subclinical thyroid dysfunction. *Endocr. Rev.* **29**, 76–131 (2008).
 66. Adriaanse, R., Brabant, G., Prank, K., Endert, E. & Wiersinga, W. M. Circadian changes in pulsatile TSH release in primary hypothyroidism. *Clin. Endocrinol. (Oxf)*. **37**, 504–510 (1992).
 67. Roelfsema, F. *et al.* Thyrotropin secretion in mild and severe primary hypothyroidism is distinguished by amplified burst mass and basal secretion with increased spikiness and approximate entropy. *J. Clin. Endocrinol. Metab.* **95**, 928–934 (2010).
 68. Moon, S. H., Lee, B. J., Kim, S. J. & Kim, H. C. Relationship between thyroid stimulating hormone and night shift work. *Ann. Occup. Environ. Med.* **28**, 53 (2016).
 69. Magrini, A. *et al.* Shift work and autoimmune thyroid disorders. *Int. J.*

- Immunopathol. Pharmacol.* **19**, 31–36 (2006).
70. Adriaanse, R., Brabant, G., Endert, E. & Wiersinga, M. M. Pulsatile untreated thyrotropin pituitary release in patients disease. *J. Clin. Endocrinol. Metab.* **77**, 205–209 (1993).
 71. Rose, S. R. Cranial irradiation and central hypothyroidism. *Trends Endocrinol. Metab.* **12**, 97–104 (2001).
 72. Baenziger, J. U. & Green, E. D. Pituitary glycoprotein hormone oligosaccharides: Structure, synthesis and function of the asparagine-linked oligosaccharides on lutropin, follitropin and thyrotropin. *Biochim. Biophys. Acta - Rev. Biomembr.* **947**, 287–306 (1988).
 73. Ikegami, K. *et al.* Tissue-specific posttranslational modification allows functional targeting of thyrotropin. *Cell Rep.* **9**, 801–809 (2014).
 74. Persani, L., Ferretti, E., Borgato, S., Faglia, G. & Beck-Peccoz, P. Circulating thyrotropin bioactivity in sporadic central hypothyroidism. *J. Clin. Endocrinol. Metab.* **85**, 3631–3635 (2000).
 75. Gesundheit, N., Magner, J. A., Chen, T. & Weintraub, B. D. Differential sulfation and sialylation of secreted mouse thyrotropin (TSH) subunits: Regulation by TSH releasing hormone. *Endocrinology* **119**, 455–463 (1986).
 76. Darzy, K. H. & Shalet, S. M. Circadian and stimulated thyrotropin secretion in cranially irradiated adult cancer survivors. *J. Clin. Endocrinol. Metab.* **90**, 6490–6497 (2005).
 77. Refetoff, S., Weiss, R. E. & Usala, S. J. The syndromes of resistance to thyroid hormone. *Endocr. Rev.* **14**, 348–399 (1993).
 78. Persani, L. *et al.* Evidence for the secretion of thyrotropin with enhanced bioactivity in syndromes of thyroid hormone resistance. *J. Clin. Endocrinol. Metab.* **78**, 1034–1039 (1994).
 79. Custro, N., Scafidi, V. & Notarbartolo, A. Pituitary resistance to thyroid hormone action with preserved circadian rhythm of thyrotropin in a postmenopausal woman. *J. Endocrinol. Invest.* **15**, 121–126 (1992).
 80. Moran, C. & Chatterjee, K. Resistance to thyroid hormone due to defective thyroid receptor alpha. *Best Pract. Res. Clin. Endocrinol. Metab.* **29**, 647–657 (2015).
 81. DeGroot, L. J. Graves' disease and the manifestations of thyrotoxicosis. in *Endotext* (eds. Feingold, K. R. *et al.*) 1–77 (MDText.com, Inc., 2000).
 82. Roelfsema, F., Pereira, A. M., Keenan, D. M., Veldhuis, J. D. & Romijn, J. A. Thyrotropin secretion by thyrotropinomas is characterized by increased pulse

- frequency, delayed and disorderliness. *J. Clin. Endocrinol. Metab.* **93**, 4052–4057 (2008).
83. Schull, J. *et al.* Effects of thyroidectomy, parathyroidectomy and lithium on circadian wheelrunning in rats. *Physiol. Behav.* **42**, 33–39 (1988).
 84. McEachron, D. L., Lauchlan, C. L. & Midgley, D. E. Effects of thyroxine and thyroparathyroidectomy on circadian wheel running in rats. *Pharmacol. Biochem. Behav.* **46**, 243–249 (1993).
 85. Beasley, L. J. & Nelson, R. J. Thyroid gland influences the period of hamster circadian oscillations. *Experientia* **38**, 870–871 (1982).
 86. Dkhissi-Benyahya, O., Gronfier, C., De Vanssay, W., Flamant, F. & Cooper, H. M. Modeling the role of mid-wavelength cones in circadian responses to light. *Neuron* **53**, 677–687 (2007).
 87. Gloss, B. *et al.* Cardiac ion channel expression and contractile function in mice with deletion of thyroid hormone receptor α or β . *Endocrinology* **142**, 544–550 (2001).
 88. Peliciari-Garcia, R. A., Bargi-Souza, P., Young, M. E. & Nunes, M. T. Repercussions of hypo and hyperthyroidism on the heart circadian clock. *Chronobiol. Int.* **35**, 147–159 (2018).
 89. Amir, S. & Robinson, B. Thyroidectomy alters the daily pattern of expression of the clock protein, PER2, in the oval nucleus of the bed nucleus of the stria terminalis and central nucleus of the amygdala in rats. *Neurosci. Lett.* **407**, 254–257 (2006).
 90. Noguchi, T., Ikeda, M., Ohmiya, Y. & Nakajima, Y. A dual-color luciferase assay system reveals circadian resetting of cultured fibroblasts by co-cultured adrenal glands. *PLoS ONE* **7**, e37093 (2012).
 91. Arendt, J. Managing jet lag: Some of the problems and possible new solutions. *Sleep Med. Rev.* **13**, 249–256 (2009).
 92. Gary, K. A. *et al.* Total sleep deprivation and the thyroid axis: Effects of sleep and walking activity. *Aviat. Space Environ. Med.* **67**, 513–519 (1996).
 93. Hirschfeld, U. *et al.* Progressive elevation of plasma thyrotropin during adaptation to simulated jet lag: effects of treatment with bright light or zolpidem. *J. Clin. Endocrinol. Metab.* **81**, 3270–3276 (1996).
 94. Polyzos, S. A. *et al.* Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. *J. Cancer Res. Clin. Oncol.* **134**, 953–960 (2008).
 95. Haymart, M. R. *et al.* Higher serum thyroid stimulating hormone level in thyroid

- nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. *J. Clin. Endocrinol. Metab.* **93**, 809–814 (2008).
96. Boelaert, K. *et al.* Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. *J. Clin. Endocrinol. Metab.* **91**, 4295–4301 (2006).
 97. Pinkerton, L. E. *et al.* Melanoma, thyroid cancer, and gynecologic cancers in a cohort of female flight attendants. *Am. J. Ind. Med.* **61**, 572–581 (2018).
 98. Liu, G. S. *et al.* Thyroid cancer risk in airline cockpit and cabin crew: a meta-analysis. *Cancers Head Neck* **3**, 7 (2018).
 99. Kiessling, S. *et al.* Enhancing circadian clock function in cancer cells inhibits tumor growth. *BMC Biol.* **15**, 1–18 (2017).
 100. Matsuo, T. *et al.* Control mechanism of the circadian clock for timing of cell division in vivo. *Science* **302**, 255–260 (2003).
 101. Gery, S. *et al.* The circadian gene *Per1* plays an important role in cell growth and DNA damage control in human cancer cells. *Mol. Cell* **22**, 375–382 (2006).
 102. Kowalska, E. *et al.* NONO couples the circadian clock to the cell cycle. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 1592–1599 (2013).
 103. Jiang, W. *et al.* The circadian clock gene *Bmall* acts as a potential anti-oncogene in pancreatic cancer by activating the p53 tumor suppressor pathway. *Cancer Lett.* **371**, 314–325 (2016).
 104. Lee, S., Donehower, L. A., Herron, A. J., Moore, D. D. & Fu, L. Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. *PLoS ONE* **5**, e10995 (2010).
 105. Fu, L., Pelicano, H., Liu, J., Huang, P. & Lee, C. C. The circadian gene *Period2* plays an important role in tumor suppression and DNA damage response in vivo. *Cell* **111**, 41–50 (2002).
 106. Papagiannakopoulos, T. *et al.* Circadian rhythm disruption promotes lung tumorigenesis. *Cell Metab.* **24**, 324–331 (2016).
 107. Gallo, C. *et al.* The bHLH transcription factor DEC1 promotes thyroid cancer aggressiveness by the interplay with NOTCH1. *Cell Death Dis.* **9**, 871 (2018).
 108. Relógio, A. *et al.* Ras-mediated deregulation of the circadian clock in cancer. *PLoS Genet.* **10**, e1004338 (2014).
 109. Altman, B. J. *et al.* MYC disrupts the circadian clock and metabolism in cancer cells. *Cell Metab.* **22**, 1009–1019 (2015).
 110. Durante, C. *et al.* The diagnosis and management of thyroid nodules. *JAMA* **319**, 914–924 (2018).

111. Sherman, S. I. Thyroid carcinoma. *Lancet* **361**, 501–511 (2003).
112. Kitahara, C. M. & Sosa, J. A. The changing incidence of thyroid cancer. *Nat. Rev. Endocrinol.* **12**, 646–653 (2016).
113. Mannic, T. *et al.* Circadian clock characteristics are altered in human thyroid malignant nodules. *J. Clin. Endocrinol. Metab.* **98**, 4446–4456 (2013).
114. Nakane, Y. & Yoshimura, T. Photoperiodic regulation of reproduction in vertebrates. *Annu. Rev. Anim. Biosci.* **7**, 173–194 (2018).
115. Ottenweller, J. E., Tapp, W. N., Pitman, D. L. & Natelson, B. H. Adrenal, thyroid, and testicular hormone rhythms in male golden hamsters on long and short days. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **253**, R321–R328 (1987).
116. Wong, C. C. *et al.* Influence of age, strain and season on diurnal periodicity of thyroid stimulating hormone, thyroxine, triiodothyronine and parathyroid hormone in the serum of male laboratory rats. *Eur. J. Endocrinol.* **102**, 377–385 (1983).
117. Wirz-Justice, A. Seasonality in affective disorders. *Gen. Comp. Endocrinol.* **258**, 244–249 (2018).
118. Dopico, X. C. *et al.* Widespread seasonal gene expression reveals annual differences in human immunity and physiology. *Nat. Commun.* **6**, 1–13 (2015).
119. Maes, M. *et al.* Components of biological variation, including seasonality, in blood concentrations of TSH, TT3, FT4, PRL, cortisol and testosterone in healthy volunteers. *Clin. Endocrinol.* **46**, 587–598 (1997).
120. Smals, A. G. H., Ross, H. A. & Kloppenborg, P. W. C. Seasonal variation in serum T3 and T4 levels in man. *J. Clin. Endocrinol. Metab.* **44**, 998–1001 (1977).
121. Bellastella, A. *et al.* Circannual rhythms of plasma growth hormone, thyrotropin and thyroid hormones in prepuberty. *Clin. Endocrinol.* **20**, 531–537 (1984).
122. Gullo, D. *et al.* Seasonal variations in TSH serum levels in athyreotic patients under L-thyroxine replacement monotherapy. *Clin. Endocrinol.* **87**, 207–215 (2017).
123. Buchinger, W., Semlitsch, G., Pongratz, R. & Rainer, B. H. F. Jahreszeitliche variationen im auftreten der hyperthyreose. *Acta Med. Austriaca* **27**, 51–53 (2000).
124. Aksten, L. A. & Sothorn, R. B. Seasonal variations in the presentation and growth of thyroid cancer. *Br. J. Cancer* **77**, 1174–1179 (1998).
125. Nakao, N. *et al.* Thyrotrophin in the pars tuberalis triggers photoperiodic

- response. *Nature* **452**, 317–322 (2008).
126. Yoshimura, T. *et al.* Light-induced hormone conversion of T₄ to T₃ regulates photoperiodic response of gonads in birds. *Nature* **426**, 178–181 (2003).
 127. Yamamura, T., Hirunagi, K., Ebihara, S. & Yoshimura, T. Seasonal morphological changes in the neuro-glial interaction between gonadotropin-releasing hormone nerve terminals and glial endfeet in Japanese quail. *Endocrinology* **145**, 4264–4267 (2004).
 128. Ono, H. *et al.* Involvement of thyrotropin in photoperiodic signal transduction in mice. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 18238–18242 (2008).
 129. Hanon, E. A. *et al.* Ancestral TSH mechanism signals summer in a photoperiodic mammal. *Curr. Biol.* **18**, 1147–1152 (2008).
 130. Bockmann, J. *et al.* Thyrotropin expression in hypophyseal pars tuberalis-specific cells is 3,5,3'-triiodothyronine, thyrotropin-releasing hormone, and Pit-1 independent. *Endocrinology* **138**, 1019–1028 (1997).
 131. Arendt, J. *Melatonin and the mammalian pineal gland.* (Chapman & Hall, 1995).
 132. Yasuo, S., Yoshimura, T., Ebihara, S. & Korf, H.W. Melatonin transmits photoperiodic signals through the MT1 melatonin receptor. *J. Neurosci.* **29**, 2885–2889 (2009).
 133. Heldmaier, G., Ortman, S. & Elvert, R. Natural hypometabolism during hibernation and daily torpor in mammals. *Respir. Physiol. Neurobiol.* **141**, 317–329 (2004).
 134. Geiser, F. & Turbill, C. Hibernation and daily torpor minimize mammalian extinctions. *Naturwissenschaften* **96**, 1235–1240 (2009).
 135. Gautier, C. *et al.* Gene expression profiling during hibernation in the European hamster. *Sci. Rep.* **8**, 1–17 (2018).
 136. Antonica, F. *et al.* Generation of functional thyroid from embryonic stem cells. *Nature* **491**, 66–71 (2012).
 137. Tamai, T. K. *et al.* Identification of circadian clock modulators from existing drugs. *EMBO Mol. Med.* **10**, e8724 (2018).
 138. Oshima, T. *et al.* Cell-based screen identifies a new potent and highly selective CK2 inhibitor for modulation of circadian rhythms and cancer cell growth. *Sci. Adv.* **5**, 1–16 (2019).
 139. Sulli, G. *et al.* Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. *Nature* **553**, 351–355 (2018).
 140. Biro, J. Specific binding of thyroid-stimulating hormone by human serum globulins. *J. Endocrinol.* **88**, 339–349 (1980).

141. Spitz, I. M. *et al.* Increased high-molecular-weight thyrotropin with impaired biologic activity in a euthyroid man. *N. Engl. J. Med.* **304**, 278–282 (1981).
142. DeCherney, G. S., Gesundheit, N., Gyves, P. W., Showalter, C. R. & Weintraub, B. D. Alterations in the sialylation and sulfation of secreted mouse thyrotropin in primary hypothyroidism. *Biochem. Biophys. Res. Commun.* **159**, 755–762 (1989).
143. Loh, T. P. *et al.* Macro-thyrotropin : a case report and review of literature. *J. Clin. Endocrinol. Metab.* **97**, 1823–1828 (2012).
144. Tamaki, H. *et al.* Novel thyrotropin (TSH) -TSH antibody complex in a woman and her neonates. *Thyroid* **5**, 299–304 (1995).
145. Constant, R. B. & Weintraub, B. D. Differences in the metabolic clearance of pituitary and serum thyrotropin (TSH) derived from euthyroid and hypothyroid rats: Effects of chemical deglycosylation of pituitary TSH. *Endocrinology* **119**, 2720–2727 (1986).
146. Asa, S. L., Kovacs, K. & Bilbao, J. M. The pars tuberalis of the human pituitary. *Virchows Arch. A* **399**, 49–59 (1983).

Acknowledgements

This work was supported by the JSPS KAKENHI Grant-in-Aid for Specially Promoted Research (26000013), for Young Scientists (B) (17K15574), the Human Frontier Science Program (RGP0030/2015), and the National Institutes of Health (PO1 AG-11412 and R01 DK-15070). WPI-ITbM is supported by the World Premier International Research Center Initiative (WPI), MEXT, Japan.

Author contributions

All author researched data for the article, contributed to discussion of the content, wrote the article and reviewed and/or edited the manuscript before submission.

Competing interests

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figure Legends




Figure 1. Hypothalamic–pituitary–thyroid axis. Thyrotropin-releasing hormone (TRH) produced in the paraventricular nucleus (PVN) is secreted from the median eminence (ME) and transported to the pituitary via the hypothalamus–hypophyseal portal system. TRH stimulates thyrotrophs to synthesize TSH in the pars distalis (PD) of the pituitary gland by upregulating mRNA levels of *TSHA* and *TSHB*. TSH stimulates the thyroid gland to produce thyroid hormones (predominantly the prohormone T₄) via the TSH receptor on the thyroid follicle cell membrane. TSH induces most of the essential events in thyroid hormone production. T₃ derived from circulating T₄ regulates synthesis and release of TRH and pars distalis TSH as part of a negative feedback loop mediated by the thyroid hormone receptor. This regulatory pathway is called the ‘hypothalamic–pituitary–thyroid axis’^{1,2}. PT, pars tuberalis; PN, pars intermedia; PI, pars nervosa.




Figure 2. The hypothalamic–pituitary–thyroid axis is under circadian regulation.

The suprachiasmatic nuclei (SCN) receives light information from the retina through the retino-hypothalamic tract (RHT) and outputs the circadian signal to hypothalamic paraventricular nucleus (PVN) via neural connections^{20,21}. In humans, thyrotropin-releasing hormone (TRH) and TSH secretions exhibit circadian rhythms^{34,35}.




Figure 3. The circadian transcriptional and translational feedback loop machinery in mammals. In the core loop, the CLOCK–BMAL1 complex binds E-boxes in promoters of target genes (*PER1*, *PER2* and *PER3*, and *CRY1* and *CRY2*, and clock-controlled genes [*CCGs*]) and activates their transcription. PERs and CRYs form complexes to inhibit CLOCK–BMAL1-mediated transcription. A second loop involves additional pairs of transcription factors such as Reverse strand of *Erbα* (REV-ERB α) and REV-ERB β and retinoic acid receptor-related orphan receptor- α (ROR α), ROR β and ROR γ . CLOCK–BMAL1 also induces REV-ERB proteins and RORs, which regulate *CLOCK* and *BMAL1* through ROR-elements (RREs) but exert opposite effects on transcription ²⁷.




Figure 4. Temporal changes of plasma TSH in human. Upper panel shows an individual profile of plasma TSH sampled at 20-min intervals for 53 h in a healthy young male volunteer. The sampling period included one night of nocturnal sleep (black bar), one night of total sleep deprivation (open bar) and one 8-h period of daytime recovery sleep (grey bar). Note that sleep deprivation was associated with a near twofold rise in nocturnal TSH levels, uncovering an inhibitory effect of sleep under normal condition. Pulsatile TSH variations are apparent throughout the sampling period. Lower panel shows mean (plus standard error of the mean) levels of plasma TSH from 11 healthy young men. The symbols are the same as in upper panel. Note that daytime recovery sleep did not suppress TSH below the daytime levels. Modified from previous data ³⁶.




Figure 5. Circadian disruption can drive thyroid diseases. (a) Endogenous factors, such as genetic defects, and exogenous factors such as chronic shift work, jet lag and sleep disturbance, disrupt the endogenous circadian timing system. A faulty circadian clock is thought to increase the risk of thyroid diseases ^{7,8}. Thyroid diseases also perturb the circadian system in a tissue-specific manner ⁶⁸. (b) Effects of a sleep debt achieved by six nights of bedtime restriction to 4 h per night and a fully rested condition on TSH concentration (modified from Ref ³⁷). Shaded areas show bedtime periods.




Figure 6. Pars tuberalis-derived TSH regulates seasonal thyroid hormone function.

Light information received by the eyes is transmitted to the pineal gland via the suprachiasmatic nuclei (SCN). Pineal melatonin secretion pattern reflects the length of nights and suppresses pars tuberalis-derived TSH expression. Long days increase production of pars tuberalis-derived TSH, which acts on ependymal cells in the hypothalamus to induce type 2 iodothyronine deiodinase (DIO2) expression through the TSH receptor–G α –cAMP signaling pathway. DIO2-induced thyroid hormone activation, through the generation of T₃ from T₄, transmits the springtime signal^{128,132}. Pars distalis-

derived TSH stimulates the thyroid gland. Pars tuberalis-derived TSH has tissue-specific *N*-glycans and forms macro-TSH complexes with immunoglobulin (IgG) and albumin in the circulation. The macro-TSH complexes are unable to stimulate the thyroid gland, and this feature prevents functional crosstalk between the two TSHs, thus preventing the production of seasonal thyroid gland overactivity ⁷³.

Table 1 Effect of circadian clock on thyroid function.

Circadian status	Intervention	species	Effect on thyroid function	references
Intact	None	Human	Rhythmic TSH secretion	34,35,38
Pacemaker ablation	SCN lesion	Rat	Rhythmic TSH secretion abolished and rhythmic $T\alpha$ expression abolished	53,54
Circadian disruption	Recurrent sleep restriction	Human	Decreased TSH rise at night	37
Clock molecules	Increased expression of DEC1	Human	Promoting thyroid cancer aggressiveness	107
Clock molecules	Rev-erba	Mouse	Circadian regulation of <i>Tshb</i> expression	56

Table 2 Effect of thyroid status on the circadian system.

Thyroid status	Symptoms or treatment	species	Effect on the circadian system	references
Hypothyroidism	Thyroidectomy	Rat	Shortened free-running period of locomotor activity rhythm, decreased amplitude of clock genes (<i>Bmal1</i> , <i>Per2</i> , <i>Nr1d1</i> and <i>Rora</i>) in heart, and altered <i>Per2</i> expression (in the bed nucleus and amygdala, not in the SCN)	83,84 , 88 , 89
Hyperthyroidism	T ₄ administration	Rat	Lengthened free-running period of locomotor activity rhythm	84
Hyperthyroidism	Thiourea administration	Hamster	Lengthened free-running period of locomotor activity rhythm	85
Hyperthyroidism	T ₃ administration	Mouse	Altered clock gene (<i>Bmal1</i> , <i>Nr1d1</i> and <i>Rora</i>) expressions in heart	88
Thyroid cancer	Cancer	Human	Abnormal clock gene expressions	113

Glossary:

Ultradian

Ultradian rhythm is a recurrent cycle with a period shorter than 24h.